No, 8 weeks of Cortiment (budesonide MMX) is NOT standard steroid treatment for ulcerative colitis in patients with primary sclerosing cholangitis
For UC patients with PSC, traditional oral corticosteroids (prednisolone/prednisone) remain the standard steroid therapy, not budesonide formulations. The evidence shows that PSC itself does not respond to corticosteroid therapy, and budesonide specifically has shown minimal benefit and potential harm in PSC patients 1, 2, 3.
Key Evidence Against Budesonide in PSC
PSC Does Not Respond to Steroids
- Routine steroid use in PSC provides no therapeutic benefit 1
- Multiple guidelines explicitly recommend against corticosteroids for PSC treatment 2
- A study of oral budesonide 9 mg daily for 1 year in PSC patients showed only marginal improvement in alkaline phosphatase but significant worsening of osteoporosis (femoral neck bone density decreased from 0.851 to 0.826 g/cm², p=0.002) 3
Standard UC Treatment in PSC Context
For the ulcerative colitis component:
- Traditional prednisolone (40 mg daily, tapered over 8 weeks) remains first-line for moderate-to-severe UC 4, 5
- Patients should be evaluated for lack of response within 2 weeks to determine need to modify therapy 4
- The 2025 BSG guidelines confirm prednisolone as the standard induction agent for UC 5
Budesonide MMX Limitations
While budesonide MMX is approved for UC, it has important constraints:
- Moderate quality evidence supports budesonide MMX 9 mg for 8 weeks in mild-to-moderate UC 6
- Most effective in left-sided disease (RR 2.98,95% CI 1.56-5.67) 6
- Less effective than mesalamine in head-to-head comparison (RR 0.72,95% CI 0.57-0.91) 6
- Real-world data during COVID-19 showed budesonide MMX had worse outcomes at 4 weeks compared to prednisolone, with 31.3% requiring rescue prednisolone 7
Critical Pitfall
The presence of PSC does not change the steroid choice for treating UC flares. However, the overall treatment strategy differs:
- UC-PSC patients have a unique phenotype: younger age at diagnosis, pancolonic involvement, but paradoxically milder disease severity 8
- They require less frequent corticosteroid use overall (OR 0.24, p=0.005) 8
- When steroids are needed, use traditional prednisolone, not budesonide
- Consider earlier escalation to biologics given the complex disease 4
Recommended Approach
- For active UC in PSC patients: Start prednisolone 40 mg daily (not budesonide)
- Taper over 8 weeks according to response 9
- Assess response at 2 weeks - if inadequate, escalate to anti-TNF therapy 4
- Never use steroids for PSC itself - they provide no benefit and cause harm 1, 2
- Monitor for steroid-related complications more carefully given PSC-related bone disease risk
The confusion may arise because budesonide MMX is marketed as "Cortiment" in some regions, but this does not make it standard therapy, particularly in the PSC-UC population where traditional corticosteroids remain the evidence-based choice when steroids are indicated.